HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Citizen Petitions May Not Preempt Agency Action Under FDA Proposed Rule

This article was originally published in The Rose Sheet

Executive Summary

Pending FDA actions cannot be the subject of a "citizen petition" submitted to the agency, a proposed rule published in the Nov. 30 Federal Register directs.

You may also be interested in...



FDA Citizen Petition Proposal Inhibits OTC Drug Review Process - CTFA

An FDA proposal to ban citizen petitions on pending regulations "appears to preclude the introduction of new data and information in the OTC drug review," the Cosmetic, Toiletry and Fragrance Association argues in Feb. 28 comments.

FDA Citizen Petition Proposal Inhibits OTC Drug Review Process - CTFA

An FDA proposal to ban citizen petitions on pending regulations "appears to preclude the introduction of new data and information in the OTC drug review," the Cosmetic, Toiletry and Fragrance Association argues in Feb. 28 comments.

Calvin Klein's Eternity Should Be Deemed "Misbranded" By FDA - Petition

Calvin Klein Cosmetics' Eternity eau de parfum should be considered "misbranded" because the fragrance contains "substances in which the chemical, physical and toxicological properties have not been thoroughly investigated and thus a warning label should appear on packaging, the Environmental Health Network asserts in a May 7 citizen petition to FDA. The group advocates for people who have been chemically injured.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel